CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD

SUITE 220

HAMPTON NJ 08827

February 9, 2017

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C.  20549

Re:Celldex Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-214882)

Ladies and Gentlemen:

In connection with the above-captioned registration statement, and pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended (the “Act”), the Company hereby requests that the effective date of the above-mentioned registration statement be accelerated to 5:00 p.m. (New York time) on Monday, February 13, 2017, or as soon thereafter as practicable.

The Company hereby acknowledges that:

·should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

·the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

·the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

[signature page follows]

Very truly yours,
CELLDEX THERAPEUTICS, INC.
By:	/s/ Avery W. Catlin
	Avery W. Catlin
	Senior Vice President and Chief Financial
	Officer